top 10 stories in Bio

Eli Lilly and Co. is looking to license experimental treatments from other drugmakers, as the company faces patent expirations in the next several years, said Jan Lundberg, president of research. "Our company situation means we're particularly interested in late-stage opportunities that can be revenue-generating in 2014," he said. The company has considered about 1,000 potential deals this year, Lundberg said. Wall Street Journal, The (09/28)